Business Context and Reporting Period
This Form 8-K Current Report was filed by AlloVir, Inc. (not Kalaris Therapeutics, Inc.) on March 17, 2021. The filing discloses a significant change in executive leadership, specifically the appointment of a new Chief Executive Officer (CEO) and the transition of the current CEO to Executive Chairman.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and corporate governance changes.
Material Changes
- CEO Appointment: The Board appointed Diana M. Brainard, M.D., as CEO, effective May 17, 2021. Dr. Brainard will remain on the Board of Directors.
- Leadership Transition: David Hallal will step down as CEO on the commencement date and continue to serve as Executive Chairman of the Board.
- Compensation Package: Dr. Brainard's employment agreement includes:
- Annual base salary of $584,000.
- Annual cash bonus targeted at 60% of base salary.
- Stock option to purchase 500,000 shares (Time-Based Option) vesting over four years.
- 30,000 Sign-On Restricted Stock Units (RSUs) vesting in one year.
- 170,000 Time-Based RSUs vesting over four years.
- Severance Provisions: In the event of termination without cause or resignation for good reason, Dr. Brainard is entitled to 36 months of base salary, 100% of the target bonus, pro-rated bonuses, COBRA reimbursement, and acceleration of unvested equity awards.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or operational outlook. The primary risk disclosed relates to the Company's potential obligation to indemnify Dr. Brainard for expenses, judgments, fines, and settlement amounts incurred in actions arising from her service as an officer. Additionally, Dr. Brainard is subject to non-competition and non-solicitation covenants for one year post-employment.
Investor Verification Checklist
- Verify the exact commencement date of Dr. Brainard's role (May 17, 2021) versus the filing date.
- Review the full text of the Executive Employment Agreement (Exhibit 10.1) for detailed definitions of "cause" and "good reason."
- Confirm the closing trading price of Common Stock on the Grant Date to determine the exercise price of the 500,000 stock options.
- Assess the impact of the leadership transition on the company's strategic direction, particularly given Dr. Brainard's background in virology and infectious diseases.